ZYUS Life Sciences Corporation announced receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (?FIH?) Clinical Trial for its lead drug product candidate, Trichomylin® softgels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 CAD | -0.95% | -3.70% | +15.56% |
05-07 | ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
04-23 | ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate | MT |
1st Jan change | Capi. | |
---|---|---|
+15.56% | 53.78M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+44.76% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- ZYUS Stock
- News ZYUS Life Sciences Corporation
- ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels